Review highlights systemic effects and shared pathways of metabolic dysfunction-associated steatotic liver disease, indicating the need for comprehensive management strategies.
Key Points
Approximately one-third of the global population is affected by metabolic dysfunction-associated steatotic liver disease.
Extrahepatic manifestations include cardiovascular disease, type 2 diabetes, and chronic kidney disease.
Key mechanisms involve insulin resistance, inflammation, and lipid metabolism dysregulation.
Emerging therapeutic strategies for metabolic dysfunction-associated steatotic liver disease are vital for effective management.